Worcester HIV Vaccine
United States
Shan Lu is a physician-scientist and global leader in vaccine science with significant experience in managing large multi-institute biomedical research and product development programmes in the field of novel vaccines. Currently, he is a Professor Emeritus in the Department of Medicine, University of Massachusetts Medical School, USA.
He was a pioneer in nucleic acid vaccines (DNA and RNA) in the early 1990s and has continuously worked to advance this field in the past three decades. He proposed the heterologous prime-boost vaccination concept and developed the world’s first polyvalent DNA/protein HIV vaccine into human clinical studies, which showed robust and broadly cross-reactive immune responses. He has over 200 publications in leading scientific journals and has co-authored over 10 specialty books.
He is a US board-certified physician in internal medicine with more than 20 years’ clinical practice. Shan has managed major NIH-funded vaccine development programmes, including GMP manufacturing, FDA IND filing and human clinical studies. He has broad biotech industry collaboration and advisory activities, and joined Worcester HIV Vaccine in 2022, serving as its Chief Scientific Officer.
Shan was the President of International Society for Vaccines (ISV) for 2011-2013 and Chair of multiple ISV annual congresses in the past decade. He is an Editor-in-Chief of Emerging Microbes and Infections journal published by Nature and Taylor & Francis. He has served on editorial boards for other leading virology and vaccine journals. He is a fellow of ISV and a fellow of the American College of Physicians.